CA 125 for the monitoring of ovarian carcinoma during primary therapy

Lavin, PT; Knapp, RC; Malkasian, George D.

doi:10.1016/0020-7292(87)90076-2

Cited by 47 publications

(38 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients with stage III-IV ovarian cancer and a CA 125 normalisation after three courses of chemotherapy and those with a CA 125 half-life < 20 days had a significant better prognosis than patients who had not normalised after the third course or who had a CA 125 half-life>20 days. This is in accordance with previous reports (Lavin et al, 1987;Sevelda et al, 1989;Mogensen et al, 1990;Redman et al, 1990).…”

Section: Patientssupporting

confidence: 94%

“…Canney et al first noted that in patients with regressing CA 125 serum levels, a shorter CA 125 half-life correlated with a good clinical response to therapy (Canney et al, 1984). Observations by Lavin et al, indicated that a failure of CA 125 to regress to normal after three courses of chemotherapy, predicted persistent disease after completion of therapy (Lavin et al, 1987). In addition, the percentage change after one course of chemotherapy was reported to be related to progression-free survival (Rustin et al, 1989) although this was not confirmed by others (Redman et al, 1990).…”

mentioning

confidence: 99%

See 1 more Smart Citation

CA 125 half-life in ovarian cancer: a multivariate survival analysis

Yedema

Kenemans²,

Voorhorst³

et al. 1993

Br J Cancer

View full text Add to dashboard Cite

Summary Serum CA 125 regression after cytoreductive surgery and during the first three courses of chemotherapy was studied in 60 ovarian cancer patients and compared to known prognostic factors.Various methods reported in the literature to calculate a CA 125 half-life value were compared. Using two exponential regression models (Van der Burg et al., 1988;Buller et al., 1991), mean half-lives in stage I-II patients after complete cytoreductive surgery were respectively 10.7 days (range: 5-23) and 9.8 days (range: 7-15). Within stage III-IV patients, a significant positive correlation was seen between survival and (a) stage III (P = 0.002), (b) residual tumour 1 cm (P = 0.02), (c) CA 125 normalisation after three courses (P = 0.003) and (d) CA 125 half-life < 20 days (P = 0.02-0.004, depending on the method used for half-life calculation).The median survival times of patients with and without a CA 125 normalisation after three courses were 27 and 14 months respectively (P = 0.003). When

show abstract

Section: Patientssupporting

confidence: 94%

mentioning

confidence: 99%

CA 125 half-life in ovarian cancer: a multivariate survival analysis

Yedema

Kenemans²,

Voorhorst³

et al. 1993

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…Cancer antigen 125 (CA 125) is the best-characterized serum marker for advanced stage ovarian cancer (3). CA 125 is elevated in Ͼ90% of patients with stage 3 and 4 ovarian cancer, whereas only 50% of patients with stage 1 disease show elevated levels.…”

Section: Introductionmentioning

confidence: 99%

Cell-Free 59 kDa Immunoreactive Integrin-Linked Kinase

Ahmed

Oliva²,

Rice³

et al. 2004

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: We reported that the expression of integrinlinked kinase (ILK) is up-regulated in ovarian carcinomas and that ovarian cancer cells have high expression of ILK. In this study, we have examined the expression of cell-free 59 kDa immunoreactive (ir)ILK in the serum and peritoneal fluid (PTF) of patients with ovarian cancer and evaluated its potential as a serum biomarker for early-stage screening and for monitoring clinical status of patients after chemotherapy treatment.Experimental Design: Thirty-six serum specimens, including normal (n ‫؍‬ 6), benign (n ‫؍‬ 6), borderline (n ‫؍‬ 4), grade 1 (n ‫؍‬ 5), grade 2 (n ‫؍‬ 5), and grade 3 (n ‫؍‬ 10), were evaluated for the expression of irILK by Western blotting. The expression of irILK was evaluated in PTF (n ‫؍‬ 10) and peritoneal washings from women with benign ovarian cysts (n ‫؍‬ 4). In addition, tissue-conditioned medium obtained from the cultures of primary ovarian tumors (n ‫؍‬ 9) was examined for the presence of irILK. Finally, the potential of serum irILK as a biomarker for ovarian cancer screening was evaluated by comparison with cancer antigen 125 (CA 125) concentrations in cancer patients before and after chemotherapy.Results: irILK expression was present in normal serum and in serum of patients with benign ovarian tumors. irILK expression was 6 -9-fold higher in the serum of patients with grade 1, grade 2, and grade 3 ovarian cancer than in the serum of healthy volunteers and patients with benign ovarian tumors (P < 0.01). Enhanced expression of irILK in the serum of ovarian cancer patients correlated with the concentration of CA 125. High expression of irILK was present in all 10 PTF tested. Tissue-conditioned medium prepared from malignant ovarian tumors had 4-fold more irILK expression than conditioned medium obtained from borderline and benign tumors (P < 0.01). irILK expression in serum of cancer patients was reduced to basal normal levels after six cycles of Taxol/carboplatin and was consistent with the change of CA 125 levels before and after chemotherapy.Conclusions: These data suggest that irILK is an ovarian tumor-associated antigen and implicates its potential not only as a biomarker for early-stage screening but also as a marker for monitoring the clinical condition of patients after treatment.

show abstract

“…Initial small studies suggested that the half-life (van der Burg et al, 1988) or regression parameter for CA125 (Buller et al, 1992) in an individual could be used to divide patients into better or worse prognostic groups, while in other studies the division was made using an optimum cut-off for the CA125 value after one, two or three courses of chemotherapy (Lavin et al, 1987;Sevelda et al, 1989). A larger study subsequently re-evaluated several of these methods in a patient group of 248 and found that the best predictive measurement was the value of the CA125 prior to the third course of treatment (Fayers et al, 1993).…”

Section: Prognosismentioning

confidence: 99%

True

2000

View full text Add to dashboard Cite

Currently the only tumour marker to have a well-defined and validated role in the management of ovarian cancer is CA125. Changes in the level of CA125 can be used as a reliable indication of response or progression according to various criteria, but it does not yet have a clear place in diagnosis or prognosis. Its value as part of a screening tool and during routine follow-up remain the subject of ongoing trials. Other markers remain experimental and do not have a well-defined contribution to make at present. © 2000 Cancer Research Campaign

show abstract

CA 125 for the monitoring of ovarian carcinoma during primary therapy

Cited by 47 publications

References 0 publications

CA 125 half-life in ovarian cancer: a multivariate survival analysis

CA 125 half-life in ovarian cancer: a multivariate survival analysis

Cell-Free 59 kDa Immunoreactive Integrin-Linked Kinase

True

Contact Info

Product

Resources

About